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Editor,  
Migraine is the most common primary headache syndrome worldwide, affecting 
approximately 12% of the Caucasian population [1]. Migraine has been associated with 
various cardiovascular [2] and psychiatric co-morbidities [3], more recently inflammatory 
disorders such as psoriasis [4] and inflammatory bowel disease [5]. As hidradenitis 
suppurativa (HS) shares common comorbidity risks, we sought to investigate the possible 
link between migraine and HS. We explored the prevalence of migraine in patients that 
attended a tertiary care hospital (Department of dermatology, Helsinki University Hospital, 
Finland) and reviewed retrospectively all the attending patients with HS diagnosis between 
January and December 2018. Age, age at onset and at diagnosis, family history, smoking, 
comorbidities, Hurley stages and affected body sites were inquired in each patient. As the 
study was based on medical reports data with no direct patient contact, no ethical 
committee statement was required. 
167 patients were included (97 women, mean age 38.4 years +/- 13.8).  The overall 
prevalence of patients with migraine in our cohort was 12.6% (n=21). Ten patients (7.0% of 
the cohort, 47.6% of the patients with migraine) had a previously diagnosed migraine at the 
time of HS diagnosis. Table 1 summarizes patients' main characteristics. Briefly, HS patients 
with migraine were mainly women (90.5%, p=0.001) with an onset of HS at an earlier age 
(17.0 vs. 27.4 years, Mann Whitney U-test, p=0.001). The patients were younger than 
without migraine (33.0 vs. 39.2 years) but without reaching significance. The prevalence was 
similar regarding family history, smoking history, body mass index, anatomical location of HS 
and Hurley stages. Among comorbidities, there was no difference regarding acne, cardio-
vascular (hypertension, arrhythmia, lower limb arteriopathy, stroke, gout) and pulmonary 
disorders (asthma, chronic bronchitis, sleep apnea), dyslipidemia, diabetes, hypothyroidism, 
or psychiatric disorders, except for bipolar disorder (p=0.001). Patients with migraine were 
more likely to have psoriasis (p=0.04), inflammatory joint disease (p=0.002), mainly 
spondyloarthropathies (p=0.005). Multivariate logistic regression (taking into account 
gender, age, smoking, psoriasis, hypertension, inflammatory joint disease and psychiatric 
disorders) showed that female gender (OR 9.8 [1.5-63.1], p=0.016), psoriasis (OR 17.2 [2.2-
136.3], p=0.007), psychiatric disorders (OR 3.7 [1.1-11.8], p=0.028) and inflammatory joint 
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diseases (OR 6.9 [1.2-38.4], p=0.027) were associated with migraine among patients with 
HS. 
A comprehensive literature search could not reveal previous reports about the possible 
association of migraine and HS. The pathophysiology of migraine involves changes in 
different parts of the central and peripheral nervous system, and complex molecular 
mechanisms (e.g. release of calcitonin gene-related peptides) [6,7]. Triggers include 
behavioral factors such as diet, stress, sleep disturbances as well as medicaments [6,7]. 
Patients with HS may share these triggering factors [8,9]. In our patient cohort, migraine 
prevalence was similar to the general population [1], but we did not perform a direct 
comparison with the general population. Apart from the earlier onset of HS in patients with 
migraine, we found that patients with migraine were more likely to have other 
comorbidities that have been previously reported. Main limitations of the study include a 
relatively small cohort size, the absence of a control group, a single tertiary center and the 
fact that the subtypes of migraine were not discriminated. Our results suggest that migraine 
is associated indirectly with other inflammatory comorbidities of HS than per se. Larger 
studies need to confirm these results.   
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Table 1. Characteristics of HS patients with and without migraine 
 Migraine 
n (%) 
No migraine 
n (%) 
P<0.05 
Chi2  
or Mann-Whitney U 
Total (N) 21 146  
Gender    
Men (%) 
Women (%) 
2 (9.5) 
19 (90.5) 
68 (46.6) 
78 (53.4) 
0.001 
Mean age (years, SD) 33.0 (11.3) 39.2 (14.0) NS 
Mean age at diagnosis 
(years, SD) 
28.4 (12.9) 34.9 (12.8) NS 
Mean age at first 
symptoms (years, SD) 
17.0 (7.8) 27.4 (11.8) 0.001  
Familial History of HS* 2/7 (28.6) 24/56 (42.8) NS 
Hurley**    
Hurley I 7 (63.6)  27 (37.5) NS 
Hurley II 3 (27.3) 30 (41.6)  
Hurley III 1 (9.1) 15 (20.8)  
Smoking history    
Ever smokers 13/20 (65) 105/138 (76.1) NS 
Active smokers 10 (50) 72 (52.1) NS 
BMI mean (SD)  33.5 (5.9) 32.3 (8.1) NS 
Comorbidities 
Weight    
Overweight and obesity 18 (85.7) 103 (70.5) NS 
Obesity 13 (61.9) 72 (49.3)  NS 
Hypertension 1 (4.8) 36 (24.6) 0.04 
Dyslipidemia 2 (9.5) 16 (10.9) NS 
Thyroid disease 3 (14.3) 15 (10.3) NS 
Diabetes type 2 1 (4.8) 25 (17.2)  NS 
Asthma  4 (19.0) 20 (13.7) NS 
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Acne 5 (23.8) 41 (28.1) NS 
Autoimmune and 
inflammatory disorders 
   
Psoriasis 4 (19.0) 9 (6.2) 0.04 
Inflammatory bowel 
disease (total)***  
1 (4.8) 6 (4.1) NS 
Inflammatory joint 
disease (total)**** 
5 (23.8) 7 (4.8) 0.002 
 
Spondyloarthropathy 3 (14.3) 3 (2.0) 0.005 
Psychiatric 
diseases***** 
12 (57.4) 48 (32.9) 0.03 
Anxiety 4 (19.0) 24 (16.4) NS 
Depression 6 (28.6) 33 (22.6) NS 
Bipolar disorder 4 (19.0) 4 (2.7) 0.001 
NS: Not significant; SD: Standard Deviation 
*Family history could be obtained in 63 patients 
**11 vs. 77 patients 
***Includes Crohn’s disease and ulcerative colitis 
****Includes reactive, rheumatoid, psoriatic arthritis and spondyloarthropathy  
*****Includes also schizophrenia, hyperactivity, binge eating disorder, anorexia, post-traumatic 
stress disorder, compulsive disorder. Several diagnoses can apply to a patient. 
 
 
